ArticleJMIR mHealth and uHealth2026
Mobile AI-Assisted Oral Lesion Triage for Community Oral Cancer Screening: Prospective Field Evaluation Study.
Article in JMIR mHealth and uHealth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: AI-based tools for oral cancer screening have shown promising performance in curated image datasets, but their performance in real-world mobile community screening workflows remains less clear. Objective: This study evaluated the prospective field performance of a parameter-locked, mobile AI-assisted oral lesion triage system embedded in a human-supervised community oral cancer screening workflow. Methods: We conducted a prospective community-based field evaluation in eastern Taiwan from June 17 to December 31, 2025. Trained nonspecialist personnel acquired standard white-light intraoral images using handheld mobile devices during routine screening. The AI system incorporated on-site image quality assessment and lesion-level risk stratification into green, yellow, and red triage categories. Technically inadequate images after repeated acquisition attempts were classified as ungradable and excluded from performance analysis. Three board-certified oral and maxillofacial specialists established an operational clinical reference standard through structured image review and consensus adjudication. The primary outcome was lesion-level identification of high-risk lesions requiring specialist referral, defined as red versus nonred triage. Diagnostic performance was estimated with Wilson 95% CIs; precision-recall performance and preconsensus specialist agreement were also assessed. Results: Among 602 screened participants, 4283 interpretable intraoral images were included in expert adjudication and lesion-level analysis. The AI system flagged 68 red lesions; 12 (17.6%) were confirmed as high risk, and 4 additional high-risk lesions were identified during expert review, yielding 16 high-risk events for the primary red-triage analysis. For high-risk lesion identification, sensitivity was 75% (12/16; 95% CI 50.5%-89.8%) and positive predictive value was 17.6% (12/68; 95% CI 10.4%-28.4%); specificity, negative predictive value, and accuracy were 98.6% (3928/3984), 99.9% (3928/3932), and 98.5% (3940/4000), respectively. Area under the receiver operating characteristic curve values were 0.957 for red, 0.931 for yellow, and 0.964 for green triage; precision-recall analysis showed area under the precision-recall curve values of 0.8235, 0.9052, and 0.9476, respectively. Preconsensus specialist agreement was high, with a Fleiss κ of 0.921 and a Gwet AC1 of 0.981. Conclusions: This mobile AI-assisted oral lesion triage system was feasibly integrated into a real-world community screening workflow operated by trained nonspecialist personnel. In this low-prevalence field setting, red triage showed moderate sensitivity and modest positive predictive value, supporting its use as human-supervised referral-prioritization support rather than autonomous diagnosis. Further multicenter studies with blinded assessment, participant-level outcomes, workflow-efficiency measures, and longitudinal follow-up are needed before clinical impact and scalability can be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.